{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T19:33:40Z","timestamp":1770060820767,"version":"3.49.0"},"reference-count":26,"publisher":"Pharmaceutical Society of Japan","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1248\/bpb.b16-00962","type":"journal-article","created":{"date-parts":[[2017,4,30]],"date-time":"2017-04-30T18:07:44Z","timestamp":1493575664000},"page":"665-674","source":"Crossref","is-referenced-by-count":13,"title":["Preparation of an Ultrafine Rebamipide Ophthalmic Suspension with High Transparency"],"prefix":"10.1248","volume":"40","author":[{"given":"Takakuni","family":"Matsuda","sequence":"first","affiliation":[{"name":"Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University"},{"name":"Formulation Research Institute, Otsuka Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Hiraoka","sequence":"additional","affiliation":[{"name":"Formulation Research Institute, Otsuka Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Urashima","sequence":"additional","affiliation":[{"name":"Department of Medical Innovations, Otsuka Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ako","family":"Ogura","sequence":"additional","affiliation":[{"name":"Formulation Research Institute, Otsuka Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiro","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Uchida M, Tabusa F, Komatsu M, Morita S, Kanbe T, Nakagawa K. Studies on 2(1H)-quinolinone derivatives as gastric antiulcer active agents. 2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propionic acid and related compounds. <i>Chem. Pharm. Bull.<\/i>, <b>33<\/b>, 3775\u20133786 (1985).","DOI":"10.1248\/cpb.33.3775"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Yamasaki K, Ishiyama H, Imaizumi T, Kanbe T, Yabuuchi Y. Effect of OPC-12759, a novel antiulcer agent, on chronic and acute experimental gastric ulcer, and gastric secretion in rats. <i>Jpn. J. Pharmacol.<\/i>, <b>49<\/b>, 441\u2013448 (1989).","DOI":"10.1254\/jjp.49.441"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Kinoshita S, Awamura S, Oshiden K, Nakamichi N, Suzuki H, Yokoi N. Rebamipide OPC-12759 in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study. <i>Ophthalmology<\/i>, <b>119<\/b>, 2471\u20132478 (2012).","DOI":"10.1016\/j.ophtha.2012.06.052"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Kinoshita S, Oshiden K, Awamura S, Suzuki H, Nakamichi N, Yokoi N, Rebamipide Ophthalmic Suspension Phase 3 Study Group. A randomized, multicenter phase 3 study comparing 2% rebamipide (POC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye. <i>Ophthalmology<\/i>, <b>120<\/b>, 1158\u20131165 (2013).","DOI":"10.1016\/j.ophtha.2012.12.022"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Urashima H, Okamoto T, Takeji Y, Shinohara H, Fujisawa S. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated <i>in vivo<\/i> model. <i>Cornea<\/i>, <b>23<\/b>, 613\u2013619 (2004).","DOI":"10.1097\/01.ico.0000126436.25751.fb"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Urashima H, Takeji Y, Okamoto T, Fujisawa S, Shinohara H. Rebamipide increases mucin-like substance contents and periodic acid Schiff reagent-positive cells density in normal rabbits. <i>J. Ocul. Pharmacol. Ther.<\/i>, <b>28<\/b>, 264\u2013270 (2012).","DOI":"10.1089\/jop.2011.0147"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Tanaka H, Fukuda K, Ishida W, Harada Y, Sumi T, Fukushima A. Rebamipide increases barrier function and attenuates TNF\u03b1-induced barrier disruption and cytokine expression in human corneal epithelial cells. <i>Br. J. Ophthalmol.<\/i>, <b>97<\/b>, 912\u2013916 (2013).","DOI":"10.1136\/bjophthalmol-2012-302868"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Ueta M, Sotozono C, Yokoi N, Kinoshita S. Rebamipide suppresses PolyI:C-stimulated cytokine production in human conjunctival epithelial cells. <i>J. Ocul. Pharmacol. Ther.<\/i>, <b>29<\/b>, 688\u2013693 (2013).","DOI":"10.1089\/jop.2012.0054"},{"key":"9","unstructured":"9) Otsuka Pharmacutical Co., Ltd., Interview form of Mucosta<sup>\u00ae<\/sup> ophthalmic suspension UD2%, 5 (2015)."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) M\u00fcller RH, Gohla S, Keck CM. State of the Art of Nanocrystals-Special Features, Production, Nanotoxicology Aspects and Intracellular Delivery. <i>Eur. J. Pharm. Biopharm.<\/i>, <b>78<\/b>, 1\u20139 (2011).","DOI":"10.1016\/j.ejpb.2011.01.007"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kondo N, Iwao T, Masuda H, Yamanouchi K, Ishihara Y, Yamada N, Haga T, Ogawa Y, Yokoyama K. Improved oral absorption of a poorly water-soluble drug, HO-221, by wet-bead milling producing particles in submicron region. <i>Chem. Pharm. Bull.<\/i>, <b>41<\/b>, 737\u2013740 (1993).","DOI":"10.1248\/cpb.41.737"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. <i>Int. J. Pharm.<\/i>, <b>125<\/b>, 91\u201397 (1995).","DOI":"10.1016\/0378-5173(95)00122-Y"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. <i>Eur. J. Pharm. Sci.<\/i>, <b>18<\/b>, 113\u2013120 (2003).","DOI":"10.1016\/S0928-0987(02)00251-8"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Sauron R, Wilkins M, Jessent V, Dubois A, Maillot C, Weil A. Absence of food effect with a 145\u2009mg nanoparticle fenofibrate tablet formulation. <i>Int. J. Clin. Pharmacol. Ther.<\/i>, <b>44<\/b>, 64\u201370 (2006).","DOI":"10.5414\/CPP44064"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K, Kimura T. Effect of particle size reduction on dissolution and oral absorption of a poorlywater-soluble drug, cilostazol, in beagle dogs. <i>J. Control. Release<\/i>, <b>111<\/b>, 56\u201364 (2006).","DOI":"10.1016\/j.jconrel.2005.11.013"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Hu J, Johnston KP, Williams RO III. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. <i>Drug Dev. Ind. Pharm.<\/i>, <b>30<\/b>, 233\u2013245 (2004).","DOI":"10.1081\/DDC-120030422"},{"key":"17","unstructured":"17) Gassmann P, List M, Schweitzer A, Sucker H. Hydrosols\u2014alternatives for the parenteral application of poorly water soluble drugs. <i>Eur. J. Pharm. Biopharm.<\/i>, <b>40<\/b>, 64\u201372 (1994)."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Hirakawa Y, Harada K. Development of methods of ultra-fine size reduction of slightly soluble medicinal crystals (2). Factors affecting the ultra-fine size reduction of oxolinic acid crystals. <i>Yakugaku Zasshi<\/i>, <b>103<\/b>, 690\u2013695 (1983).","DOI":"10.1248\/yakushi1947.103.6_690"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Hirakawa Y, Harada K. Studies on development of the ultrafine size reduction method of slightly soluble medicinal crystals. V. Size reduction of phenytoin and phenobarbital. <i>Yakugaku Zasshi<\/i>, <b>104<\/b>, 91\u201396 (1984).","DOI":"10.1248\/yakushi1947.104.1_91"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Chan HK, Kwok PCL. Production methods for nanodrug particles using the bottom-up approach. <i>Adv. Drug Deliv. Rev.<\/i>, <b>63<\/b>, 406\u2013416 (2011).","DOI":"10.1016\/j.addr.2011.03.011"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Vehring R. Pharmaceutical particle engineering <i>via<\/i> spray drying. <i>Pharm. Res.<\/i>, <b>25<\/b>, 999\u20131022 (2008).","DOI":"10.1007\/s11095-007-9475-1"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Hasegawa S, Sekino H, Matsuoka O, Saito K, Sekino H, Morikawa A, Uchida K, Koike M, Azuma J. Bioequivalence of Rebamipide Granules and Tablets in Healthy Adult Male Volunteers. <i>Clin. Drug Investig.<\/i>, <b>23<\/b>, 771\u2013779 (2003).","DOI":"10.2165\/00044011-200323120-00002"},{"key":"23","unstructured":"23) Hisamitsu I, Hagihara T. The nano-sized emulsion by the big share stress by jet-flow method. <i>Fragrance Journal<\/i>, <b>31<\/b>, 69\u201373 (2003)."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Van de Hulst HC. <i>Light Scattering by Small Particles<\/i>. Wiley, New York, NY (1957).","DOI":"10.1063\/1.3060205"},{"key":"25","unstructured":"25) Saitoh M. Properties and Applications of Ultra fine Ceramic Powders. <i>Powder science &amp; engineering<\/i>, <b>30<\/b>, 35\u201340 (1998)"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. <i>Int. J. Pharm.<\/i>, <b>340<\/b>, 126\u2013133 (2007).","DOI":"10.1016\/j.ijpharm.2007.03.011"}],"container-title":["Biological &amp; Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/5\/40_b16-00962\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T11:34:04Z","timestamp":1569152044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/5\/40_b16-00962\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b16-00962","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}